-+ 0.00%
-+ 0.00%
-+ 0.00%

Kezar Life Sciences Q3 EPS $(1.53) Beats $(2.08) Estimate

Benzinga·11/12/2025 21:33:21
Listen to the news
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $(2.08) by 26.3 percent. This is a 44.96 percent increase over losses of $(2.78) per share from the same period last year.